AbCellera Biologics PE ratio ABCL

Share price divided by earnings per share over the last twelve months, since 2022.

Today, Oct 23, 2026: n/m; losses over the last year
Last meaningful: 13.6×; Apr 2023
Peer median: 24.3×

AbCellera Biologics has no meaningful PE ratio today: it lost $0.54 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Apr 2023, at 13.6×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	13.6×	11.9×	16.8×
2022	12.7×	11.1×	21.4×

Against its peers

Companies in Drug Manufacturers - General nearest AbCellera Biologics' size, closest first, today.

Company	PE ratio
ABCLAbCellera Biologics	n/m
OGNOrganon	17.9×
LQDALiquidia	30.7×
ARQTArcutis Biotherapeutics	142×
INDVIndivior Pharmaceuticals	12.4×
NRIXNurix Therapeutics	11.0×
PBHPrestige Consumer Healthcare	13.4×
KNSAKiniksa Pharmaceuticals International	79.1×
LGNDLigand Pharmaceuticals	32.3×
HRMYHarmony Biosciences	11.7×
AMRXAmneal Pharmaceuticals	41.6×
Peer median	24.3×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on AbCellera Biologics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.